date:Mar 15, 2023
r at Nutreco.
That is why we are pleased to invest further to support BlueNalus ongoing development and commercialization efforts and the cell-cultured industry at large.
Path to commercial viability
This agreement complements BlueNalus prior announcement regarding its large-scale commercialization plans and business differentiation with whole muscle product forms; a non-GMO, single-cell suspension line and proprietary lipid-loading technology for continuous production.
Our team has achieve